KR940002255B1 - 설파이드의 제조방법 - Google Patents

설파이드의 제조방법 Download PDF

Info

Publication number
KR940002255B1
KR940002255B1 KR1019860001769A KR860001769A KR940002255B1 KR 940002255 B1 KR940002255 B1 KR 940002255B1 KR 1019860001769 A KR1019860001769 A KR 1019860001769A KR 860001769 A KR860001769 A KR 860001769A KR 940002255 B1 KR940002255 B1 KR 940002255B1
Authority
KR
South Korea
Prior art keywords
methyl
ppm
thiazole
thiazol
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019860001769A
Other languages
English (en)
Korean (ko)
Other versions
KR860007235A (ko
Inventor
슈오이네만 칼-하인즈
뒤르크하이머 발터
블룸바흐 유르겐
림베르트 미카엘
쇼를렘머 한스-울리히
디크나이테 게르하르트
세드라섹 한스-하르알트
Original Assignee
훽스트 아크티엔게젤샤프트
하인리히 벡커,베른하르트 벡크
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 훽스트 아크티엔게젤샤프트, 하인리히 벡커,베른하르트 벡크 filed Critical 훽스트 아크티엔게젤샤프트
Publication of KR860007235A publication Critical patent/KR860007235A/ko
Application granted granted Critical
Publication of KR940002255B1 publication Critical patent/KR940002255B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
    • C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/70—Sulfur atoms
    • C07D277/74—Sulfur atoms substituted by carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
KR1019860001769A 1985-03-12 1986-03-12 설파이드의 제조방법 Expired - Fee Related KR940002255B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE3508665 1985-03-12
DE19853508665 DE3508665A1 (de) 1985-03-12 1985-03-12 Heterocyclische sulfide und ihre anwendung als immunmodulatoren
DEP3508665.3 1985-03-12

Publications (2)

Publication Number Publication Date
KR860007235A KR860007235A (ko) 1986-10-10
KR940002255B1 true KR940002255B1 (ko) 1994-03-19

Family

ID=6264870

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860001769A Expired - Fee Related KR940002255B1 (ko) 1985-03-12 1986-03-12 설파이드의 제조방법

Country Status (21)

Country Link
US (1) US4762848A (enExample)
EP (1) EP0194572B1 (enExample)
JP (2) JPS61212590A (enExample)
KR (1) KR940002255B1 (enExample)
AR (1) AR247738A1 (enExample)
AT (1) ATE70973T1 (enExample)
AU (1) AU584993B2 (enExample)
CA (1) CA1268769A (enExample)
DE (2) DE3508665A1 (enExample)
DK (1) DK165110C (enExample)
ES (1) ES8801505A1 (enExample)
FI (1) FI87203C (enExample)
GR (1) GR860648B (enExample)
HU (1) HU199441B (enExample)
IE (1) IE58875B1 (enExample)
IL (1) IL78090A (enExample)
NO (1) NO167386C (enExample)
NZ (1) NZ215425A (enExample)
PH (1) PH24659A (enExample)
PT (1) PT82167B (enExample)
ZA (1) ZA861779B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047540A (en) * 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives
DE3816603A1 (de) * 1988-05-16 1989-11-30 Behringwerke Ag Verwendung des thiazol-derivates tiprotimod zur herstellung eines mittels zur therapie von virusinfektionen
DE3915094A1 (de) 1989-05-09 1991-01-10 Hoechst Ag Verfahren zur herstellung von 2-mercapto-4-methyl-1,3-thiazol-5-yl-essigsaeure und deren ester
TW252112B (enExample) * 1993-08-19 1995-07-21 Pfizer
WO1999015524A1 (en) * 1997-09-23 1999-04-01 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivatives
US20030013846A1 (en) * 2001-05-03 2003-01-16 Bing Wang Pyruvate derivatives
TWI359810B (en) * 2004-11-04 2012-03-11 Mitsubishi Tanabe Pharma Corp Carboxylic acid derivative containing thiazole rin
CA2741300A1 (en) 2008-10-29 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2022046625A1 (en) * 2020-08-26 2022-03-03 The Lubrizol Corporation 2,5-dimercapto-1,3,4-thiadiazole ("dmtd") metal salt derivatives

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR837278A (fr) * 1937-10-02 1939-02-07 Materiel Telephonique Dispositifs de sondage utilisant des ondes électro-magnétiques
US2776976A (en) * 1952-10-21 1957-01-08 Monsanto Chemicals Halogen substituted unsaturated thiazolylthioethers
US2886487A (en) * 1955-08-22 1959-05-12 Ortho Pharma Corp Quaternary ammonium salt and n-thiotrichloromethyl hydantoin vaginal composition
BE591151A (fr) * 1959-05-28 1960-11-23 Hoffmann La Roche Procédé pour la préparation de mono- et dihydrazino-triazines.
AT238200B (de) * 1962-03-27 1965-01-25 Degussa Verfahren zur Herstellung von neuen Pyridinderivaten
DE1695093A1 (de) * 1965-10-21 1970-12-10 Geigy Ag J R Neue Imidazolderivate
US4139635A (en) * 1967-02-21 1979-02-13 L'oreal Cysteamine derivatives for oral treatment of seborrhea
US3950542A (en) * 1967-02-21 1976-04-13 L'oreal Cysteamine derivatives for oral treatment of seborrhea
LU53029A1 (enExample) * 1967-02-21 1968-08-27
US4035492A (en) * 1967-02-21 1977-07-12 L'oreal Oral treatment of seborrhea with cysteamine derivatives
FR7303M (enExample) * 1967-03-07 1969-09-29
US3671643A (en) * 1969-09-15 1972-06-20 Oreal Treatment of excessive sebaceous glands secretion with substituted cysteamine compounds
DE2129012A1 (de) * 1971-06-11 1973-01-04 Merck Patent Gmbh Azol-derivate
DE2165554A1 (de) * 1971-12-30 1973-07-05 Bayer Ag Verfahren zur herstellung von 1,2,4triazin-5-on-derivaten
US3907822A (en) * 1973-06-11 1975-09-23 Squibb & Sons Inc Anti-inflammatory (2-benzimidazoylthio)alkylamidoximes
DE2359922A1 (de) * 1973-12-01 1975-06-05 Hoechst Ag (1-alkyl-5-nitro-imidazolyl-2-alkyl)- heteroaryl-verbindungen und verfahren zu ihrer herstellung
GB1462521A (en) * 1974-02-11 1977-01-26 Wyeth John & Brother Ltd Triazole derivatives
FR2285867A1 (fr) * 1974-09-30 1976-04-23 Lafon Labor Derives du diphenylsulfoxyde
US4107438A (en) * 1974-09-30 1978-08-15 Victor Lafon Cyclic phenylsulphinyl-amidine derivatives
US4022607A (en) * 1975-06-09 1977-05-10 Sandoz, Inc. Substituted oxazoles and thiazoles as herbicides
DE2533604A1 (de) * 1975-07-26 1977-02-10 Bayer Ag 2-substituierte 5-trifluormethyl1,3,4-thiadiazole, verfahren zu ihrer herstellung sowie ihre verwendung als fungizide und insektizide
FR2319346A1 (fr) * 1975-07-31 1977-02-25 Wellcome Found Medicament comprenant une association d'un agent anti-inflammatoire et d'un imidazole ou d'un benzimidazole
US4002624A (en) * 1976-01-26 1977-01-11 The Dow Chemical Company Substituted-3-thio-1,2,4-triazines
US4202901A (en) * 1976-03-04 1980-05-13 Ciba-Geigy Corporation 2-Pyridinecarbonitrile compounds
US4018923A (en) * 1976-03-10 1977-04-19 Eli Lilly And Company 5,6-Diaryl-1,2,4-triazines as topically-active anti-inflammatory agents
FR2368278A1 (fr) * 1976-10-25 1978-05-19 Fabre Sa Pierre Nouveaux medicaments antalgiques contenant des triazines 1-2-4
US4182769A (en) * 1977-02-09 1980-01-08 E. I. Du Pont De Nemours And Company Anti-inflammatory 1-substituted-4,5-diaryl-2-(substituted-thio) imidazoles and their corresponding sulfoxides and sulfones
AT367296B (de) * 1977-04-12 1982-06-25 Ciba Geigy Ag Verfahren zur kurativen und prophylaktischen bekaempfung von parasitaeren helminthen
CH634306A5 (de) * 1977-04-12 1983-01-31 Ciba Geigy Ag Benzimidazolderivate, verfahren zu ihrer herstellung und anthelmintische mittel enthaltend diese verbindungen als wirkstoffe.
JPS5416491A (en) * 1977-05-17 1979-02-07 Diamond Shamrock Corp Substituted 1*2*44triazines having pharmacological action
US4157392A (en) * 1977-05-17 1979-06-05 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
US4251527A (en) * 1977-05-17 1981-02-17 Diamond Shamrock Corporation Pharmacologically active substituted 1,2,4-triazines
US4396625A (en) * 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4379159A (en) * 1980-10-16 1983-04-05 E. I. Du Pont De Nemours & Company Antiinflammatory 2-substituted-thio-4,5-dihydro-4,5-diaryl-1H-imidazoles
US4451471A (en) * 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
DE3118126A1 (de) * 1981-05-07 1982-12-02 Bayer Ag, 5090 Leverkusen Sulfenamide zur verwendung in arzneimitteln
DE3216416A1 (de) * 1982-05-03 1983-11-03 Bayer Ag, 5090 Leverkusen Heteroarylthiovinyl-verbindungen, ein verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
DE3336846A1 (de) * 1983-10-11 1985-04-25 Bayer Ag, 5090 Leverkusen Neue 2-mercaptothiazolderivate, verfahren zu deren herstellung sowie die verwendung von 2-mercaptothiazolderivaten in arzneimitteln
ZA854550B (en) * 1984-06-18 1986-04-30 Smithkline Beckman Corp Leukotriene antagonists

Also Published As

Publication number Publication date
DE3683172D1 (de) 1992-02-13
DK165110B (da) 1992-10-12
EP0194572B1 (de) 1992-01-02
HUT44524A (en) 1988-03-28
IL78090A (en) 1991-08-16
FI87203C (fi) 1992-12-10
PT82167B (pt) 1988-07-29
JPH0380792B2 (enExample) 1991-12-26
IE58875B1 (en) 1993-12-01
GR860648B (en) 1986-07-11
ZA861779B (en) 1986-10-29
DK165110C (da) 1993-03-01
DE3508665A1 (de) 1986-09-18
CA1268769A (en) 1990-05-08
AU5460686A (en) 1986-10-16
AU584993B2 (en) 1989-06-08
ES552841A0 (es) 1988-01-16
FI860981A0 (fi) 1986-03-10
KR860007235A (ko) 1986-10-10
NO167386B (no) 1991-07-22
IL78090A0 (en) 1986-07-31
ATE70973T1 (de) 1992-01-15
NZ215425A (en) 1990-01-29
DK108686D0 (da) 1986-03-10
ES8801505A1 (es) 1988-01-16
JPS61212590A (ja) 1986-09-20
AR247738A1 (es) 1995-03-31
PH24659A (en) 1990-09-07
FI87203B (fi) 1992-08-31
IE860631L (en) 1986-09-12
HU199441B (en) 1990-02-28
JPS6452719A (en) 1989-02-28
PT82167A (de) 1986-04-01
EP0194572A1 (de) 1986-09-17
FI860981L (fi) 1986-09-13
DK108686A (da) 1986-09-13
US4762848A (en) 1988-08-09
NO860907L (no) 1986-09-15
NO167386C (no) 1991-10-30

Similar Documents

Publication Publication Date Title
KR101403164B1 (ko) 베타-락타마아제 저해제 및 모노박탐 항생물질의 유용한조합
US4680390A (en) Esters of 7-[2-(2-aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methyl-ceph-3-em-4-carboxylic acid
DE2716707A1 (de) Cephemderivate und verfahren zu ihrer herstellung
US4873346A (en) Substituted benzothiazoles, benzimidazoles, and benzoxazoles
KR940002255B1 (ko) 설파이드의 제조방법
HU186753B (en) Process for producing 7-acylamino-3-vinyl-ceph-3-eme-4-carboxylic acid derivatives
JP2972377B2 (ja) カテコール誘導体、その薬学的に許容しうる塩およびエステルならびにそれらを含有する医薬組成物
JPH0338278B2 (enExample)
WO2001005756A1 (en) 3-arylsulfonyl-2-(substituted methyl)propanoic acid derivates as matrix metalloproteinase inhibitors
JP2529093B2 (ja) セファロスポリン中間体の製造方法
JPH10510258A (ja) セフェム化合物およびその医薬用途
AU594943B2 (en) Heterocyclic disulfides and their use as immunodulators
US4172198A (en) 7-(N-substituted-2-phenylglycinamido)-3-substituted-3-cephem-4-carboxylic acid compounds and preparation thereof
US3535331A (en) Water-soluble 2-substituted benzimidazole hypophosphite salts
CA1292990C (en) Heterocyclic disulfides and their use as immunomodulators
CA2040011C (en) Thiazole and imidazole derivatives and antiulcer composition containing same
US5484928A (en) 2-(2-aminothiazol-4-yl)-2-oxoacetic acid derivatives
IE43376B1 (en) 7-/ -amino-w-(3,4-methylenedioxyphenyl) acylamido/cephalosporanic acid derivatives
IE43377B1 (en) 7-/ amino-w-(2,3-methylenedioxyphenyl) acylamido/cephalosporanic acid derivatives
KR860002184B1 (ko) 세펨 유도체의 제조방법
US5252592A (en) Tetrazoleacetic acid derivatives having aldose reductase inhibitory activity
JPH07625B2 (ja) セファロスポリン中間体の製造方法
JPH03204885A (ja) 新規セファロスポリン系化合物
EP0178822A2 (en) 2-Guanidino-4-(2-methyl-4-imidazolyl)thiazoles in the treatment of rheumatoid arthritis
DK142175B (da) Analogifremgangsmaade til fremstilling af thiazolo- eller 1,3,4-thiadiazolo-(3,2-)-pyrimidin7-on-5-carboxylsyrederivater

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19970320

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19970320

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000